Skip to content
Join our community and subscribe to our free weekly newsletter
Subscribe
Toggle Navigation
Latest News
Articles
Live Talks
Trials Update
Prevention & Risk Factors
Science-Backed Dementia Prevention
Alzheimer’s Genetics & Risk Factors
Menopause
Long COVID
Dementias
Alzheimer’s Disease
Vascular Dementia
Frontotemporal Dementia (FTD)
Lewy Body Dementia
Traumatic Brain Injury & CTE
Brain Disorders
Mild Cognitive Impairment (MCI)
Parkinson’s Disease
Getting Diagnosed
Diagnosis
Journey to Diagnosis
Genetic Testing
Alzheimer’s Biomarkers
Diversity and Dementia
Caregivers
Caregiver Voices
Learning Guides
Search for:
Search for:
Oligomannate
Tidal Change: China Takes Alzheimer’s ‘Seaweed Drug’ Off the Market
Global Alzheimer’s Trial For China’s ‘Seaweed Drug’ Halted
The Gut Microbiome in Aging and Cognitive Health
As Our Oceans Change, Drugmakers Dive Deep for an Alzheimer’s Cure
Now Recruiting: U.S. Trials for Alzheimer’s “Seaweed Drug” Oligomannate
Seaweed Alzheimer’s Drug Approved for U.S. Clinical Trials — First New Drug in 17 years
China’s ‘Seaweed’ Alzheimer’s Drug Is Now Available to Patients
Could China’s ‘Seaweed Drug’ Treat Alzheimer’s? Experts Remain Cautious
China Approves ‘Seaweed Drug’ for Treatment of Alzheimer’s
Page load link
Go to Top